O documento como fonte primária nos estudos da enfermagem e da saúde: uma reflexão / El documento como fuente primaria en los estudios de enfermería y salud: una reflexión / The document as a primary source in nursing and health studies: a reflection

RESUMO Objetivo analisar as interfaces e distinções histórico-conceituais acerca dos estudos documentais, enquanto método de pesquisa, na área da Enfermagem e da saúde. Método ensaio teórico de cunho reflexivo, elaborado com base na literatura nacional e internacional sobre o tema. Resultados apresenta uma teorização acerca da evolução conceitual dos documentos e as contribuições advindas da Escola de Annales, com ênfase na expansão documental, também referida como revolução. Fundamenta conceitos, organização, coleta e análise dos dados documentais e as relações com a pesquisa histórica aplicada à Enfermagem e, por conseguinte, à saúde. Aborda a produção do conhecimento como parte do desenvolvimento da educação e da pesquisa em Enfermagem, no Brasil. Conclusões e implicações para a prática a apropriação das fontes documentais e dos métodos no desenvolvimento da pesquisa, do ensino e da assistência à saúde aguçam a curiosidade e ampliam a capacidade de análise, de crítica e de autonomia de grupos de interesse e estudiosos, esperando-se, com isso, a ampliação do conhecimento relacionado à profissão.

RESUMEN Objetivo analizar las interfaces y distinciones histórico-conceptuales acerca de los estudios documentales cómo método de investigación en el campo de la Enfermería y la salud. Método ensayo teórico con carácter reflexivo basado en la literatura nacional e internacional sobre el tema. Resultados presenta una teorización sobre la evolución conceptual de los documentos y los aportes de la Escuela de los Annales con énfasis en la expansión documental. Apoya conceptos, organización, recolección y análisis de datos documentales y sus relaciones con la investigación histórica en Enfermería y, por consiguiente, en salud. Aborda la producción de conocimiento como parte de la evolución de la educación y la investigación en Enfermería en Brasil. Conclusiones e implicaciones para la práctica la apropiación de fuentes y métodos documentales en el desarrollo de la investigación, la docencia y la salud agudiza la curiosidad y amplía la capacidad de análisis, crítica y autonomía de grupos de interés y académicos.

ABSTRACT Objective to analyze the historical-conceptual interfaces and distinctions regarding documentary studies as a research method in the field of Nursing and health. Method theoretical essay with a reflective nature based on national and international literature on the subject. Results the study presents a theorization about the conceptual evolution of documents and the contributions of Annales School, with emphasis on document expansion, also referred to as revolution. It supports concepts, organization, collection and analysis of documentary data and its relationships with historical research applied to Nursing and, therefore, to health. It addresses the production of knowledge as part of the evolution of education and research in Nursing in Brazil. Conclusions and implications for practice the appropriation of documentary sources and methods in the development of research, teaching and health care sharpens curiosity and expands the capacity for analysis, criticism and autonomy of interest groups and scholars, being expected, with this, the expansion of knowledge related to the profession.

Centro de Histoterapia Placentaria "Dr. Carlos Manuel Miyares Cao", 35 años de entrega a la Ciencia Cubana / "Dr. Carlos Miyares Cao" Placental Histotherapy Center, 35 years of dedication to Cuban Science

Introducción: La fundación del Centro de Histoterapia Placentaria, el 25 de abril de 1986, como resultado de la repercusión internacional por el nuevo método cubano del tratamiento del vitiligo con un medicamento obtenido de la placenta humana, descubierto por el doctor Carlos Manuel Miyares Cao, favoreció el desarrollo de las Ciencias Médicas en Cuba. Institución de prestigio, que arribó este 2021 a su Aniversario 35, y que ha obtenido un gran impacto en la salud y calidad de vida de personas con enfermedades dermatológicas como vitiligo, psoriasis y alopecia. Objetivo: Conocedores de la importancia de salvaguardar los hitos históricos como elementos imprescindibles en la trayectoria científico-social de una institución, nos propusimos exponer los componentes fundamentales que conforman este Centro de Histoterapia Placentaria e incentivar a las nuevas generaciones para continuar la labor investigativa que realiza este y la necesidad de preservar su historia. Material y Métodos: Se realizó una investigación histórico-bibliográfica de los documentos compilados que se conservan en la Biblioteca del Centro para poder fundamentar este artículo. Desarrollo: Se incluyen los aspectos esenciales que avalan la historia del Centro y la imbricación científico-social-humana en este del Dr. Carlos Manuel Miyares Cao. Conclusiones: Históricamente ofrecer toda la trayectoria de este Centro de Histoterapia Placentaria y su significación e importancia para la Ciencia Cubana, así como transmitir a especialistas, médicos y, en general, trabajadores de la salud, su destacada labor en la recuperación de graves enfermedades que aquejan a la población mundial(AU)

Introduction: As a result of the international repercussion of a new Cuban method for treating vitiligo with a drug obtained from human placenta, discovered by Dr. Carlos Manuel Miyares Cao, the Placental Histotherapy Center was founded on April 25, 1986 to support the development of Medical Sciences in Cuba. This prestigious institution, which arrived to its 35th Anniversary this year, has made a significant impact on the health and quality of life of people with dermatological diseases such as vitiligo, psoriasis and alopecia. Objective: Knowing the importance of safeguarding historical milestones as essential elements in the scientific and social trajectory of an institution, we intend to present the fundamental components that make up the Placental Histotherapy Center as well as to encourage new generations to continue the research work carried out in this center and the need to preserve its history. Material and Methods: A historical and bibliographical investigation of the documents preserved in the Library of the Center was carried out to base this article. Development: The essential aspects that support the history of the Center as well as the scientific, social and human involvement of Dr. Carlos Manuel Miyares Cao in this process are included. Conclusions: Our objective is to offer the entire trajectory of the Placental Histotherapy Center and its significance and importance for Cuban Science from a historical perspective as well as to inform specialists, doctors, and health workers in general about its outstanding work related to the recovery from serious diseases that afflict the world's population(AU)

25 years of ERß: a personal journey.

Summary: After the discovery of ERß, a novel role for dihydrotestosterone (DHT) in estrogen signaling was revealed. Instead of just being a better androgen, DHT was found to be a precursor of the ERß agonist 5α-androstane-3ß, 17ß-diol (3ßAdiol), an estrogen which does not require aromatase for its synthesis. ERß was found to oppose androgen signaling and thus is a potential target for treatment of prostate cancer. ERß was also found to have effects that were independent of androgen signaling, particularly in the CNS. Although in rodent models of neurodegenerative diseases (Parkinson's disease, multiple sclerosis, and Alzheimer's disease), ERß agonists are very effective in relieving symptoms and improving pathologies, this has not proven to be the case in humans. In this review we will focus on the main differences in ERß signaling between rodents and humans and will make the point that a very important difference between the two species is in the splice variants which are expressed in humans and not rodents. The main conclusion at this point is that before we think of using ERß agonists clinically, much more work on ERß signaling in the human or in primates needs to be done.

HDL in the 21st Century: A Multifunctional Roadmap for Future HDL Research.

Low high-density lipoprotein cholesterol (HDL-C) characterizes an atherogenic dyslipidemia that reflects adverse lifestyle choices, impaired metabolism, and increased cardiovascular risk. Low HDL-C is also associated with increased risk of inflammatory disorders, malignancy, diabetes, and other diseases. This epidemiologic evidence has not translated to raising HDL-C as a viable therapeutic target, partly because HDL-C does not reflect high-density lipoprotein (HDL) function. Mendelian randomization analyses that have found no evidence of a causal relationship between HDL-C levels and cardiovascular risk have decreased interest in increasing HDL-C levels as a therapeutic target. HDLs comprise distinct subpopulations of particles of varying size, charge, and composition that have several dynamic and context-dependent functions, especially with respect to acute and chronic inflammatory states. These functions include reverse cholesterol transport, inhibition of inflammation and oxidation, and antidiabetic properties. HDLs can be anti-inflammatory (which may protect against atherosclerosis and diabetes) and proinflammatory (which may help clear pathogens in sepsis). The molecular regulation of HDLs is complex, as evidenced by their association with multiple proteins, as well as bioactive lipids and noncoding RNAs. Clinical investigations of HDL biomarkers (HDL-C, HDL particle number, and apolipoprotein A through I) have revealed nonlinear relationships with cardiovascular outcomes, differential relationships by sex and ethnicity, and differential patterns with coronary versus noncoronary events. Novel HDL markers may also have relevance for heart failure, cancer, and diabetes. HDL function markers (namely, cholesterol efflux capacity) are associated with coronary disease, but they remain research tools. Therapeutics that manipulate aspects of HDL metabolism remain the holy grail. None has proven to be successful, but most have targeted HDL-C, not metrics of HDL function. Future therapeutic strategies should focus on optimizing HDL function in the right patients at the optimal time in their disease course. We provide a framework to help the research and clinical communities, as well as funding agencies and stakeholders, obtain insights into current thinking on these topics, and what we predict will be an exciting future for research and development on HDLs.

Strategies for Using Muramyl Peptides - Modulators of Innate Immunity of Bacterial Origin - in Medicine.

The spread of infectious diseases is rampant. The emergence of new infections, the irrational use of antibiotics in medicine and their widespread use in agriculture contribute to the emergence of microorganisms that are resistant to antimicrobial drugs. By 2050, mortality from antibiotic-resistant strains of bacteria is projected to increase up to 10 million people per year, which will exceed mortality from cancer. Mutations in bacteria and viruses are occurring faster than new drugs and vaccines are being introduced to the market. In search of effective protection against infections, new strategies and approaches are being developed, one of which is the use of innate immunity activators in combination with etiotropic chemotherapy drugs. Muramyl peptides, which are part of peptidoglycan of cell walls of all known bacteria, regularly formed in the body during the breakdown of microflora and considered to be natural regulators of immunity. Their interaction with intracellular receptors launches a sequence of processes that ultimately leads to the increased expression of genes of MHC molecules, pro-inflammatory mediators, cytokines and their soluble and membrane-associated receptors. As a result, all subpopulations of immunocompetent cells are activated: macrophages and dendritic cells, neutrophils, T-, B- lymphocytes and natural killer cells for an adequate response to foreign or transformed antigens, manifested both in the regulation of the inflammatory response and in providing immunological tolerance. Muramyl peptides take part in the process of hematopoiesis, stimulating production of colony-stimulating factors, which is the basis for their use in the treatment of oncological diseases. In this review we highlight clinical trials of drugs based on muramyl peptides, as well as clinical efficacy of drugs mifamurtide, lycopid, liasten and polimuramil. Such a multifactorial effect of muramyl peptides and a well-known mechanism of activity make them promising drugs in the treatment and preventing of infectious, allergic and oncological diseases, and in the composition of vaccines.

Steve Oroszlan: A Personal Perspective.

My memories of Steve go back over 50 years. While precise dates are no longer in my memory bank, circumstances and emotions remain alive and easy to recall. These memories tell the story of a remarkable human being, a true practitioner of his craft always, faithful to the basic principles of scientific pursuit, with integrity, honesty, and enthusiasm well beyond the norm. We had a professional symbiotic relationship that lasted over 20 years, resulting in over 50 publications in scientific journals and meeting abstracts. During that time, our fortunes rose in tandem, and when it was time to go our separate ways, he was more than ready to flourish on his own. Our personal friendship remained constant, and we enjoyed sharing meals and stories with family and friends over the years. In retrospect, I take pride in having played a role in a portion of his remarkable scientific journey. A few key anecdotes will illustrate some aspects of this summary. By way of a disclaimer, this is not a comprehensive review of the vast field of viral oncology and the selection of references is intentionally narrow. No slight is intended to the many outstanding investigators that were our contemporaries and at times collaborators during the period from the early 70s to the mid-80s.

HIV Vaccine Development: 35 Years of Experimenting in the Funding of Biomedical Research.

Funding vaccine development research is more complicated than simply putting out an announcement of funds available. The funders must decide whether product development can be accomplished by purely applied research, or whether more fundamental knowledge is needed before product development can be started. If additional basic knowledge is needed, identifying the specific area of the knowledge gap can be a challenge. Additionally, when there appears to be a clear path of applied research sometimes obstacles are encountered that require a return to more basic work. After deciding on the work to be done, funders must attract the scientists with the broad range of needed skills to cover all the stages of development. Collaborations must be promoted and alliances with other funders and industry must be developed. Funders use multiple tools and strategies to accomplish these tasks with varying success.

Historical review of the Department of Physiology on the 75th anniversary of the Instituto Nacional de Cardiología Ignacio Chávez / Reseña histórica del Departamento de Fisiología en el 75 aniversario del Instituto Nacional de Cardiología Ignacio Chávez

Abstract The Physiology Department has played an important role in the development of physiology in Mexico since its beginnings. It was founded by Dr. Arturo Rosenblueth in 1947. Many of the original researchers participated in the formation of the Mexican Society of Physiological Sciences. Researchers belonging to this department have given origin to an important national research center (CINVESTAV) and to numerous groups and departments within the Instituto Nacional de Cardiología such as the Valves department in the basement of the main building of the institute, the department of molecular biology situated in the Anexo de Investigación, and a laboratory in the translational medicine unit. The physiology department has importantly contributed to the development of research in the Instituto Nacional de Cardiología.

Resumen El Departamento de Fisiología ha desempeñado un papel importante en el desarrollo de la fisiología en México desde sus inicios. Fue fundado por el Dr. Arturo Rosenblueth en 1947. Muchos de sus investigadores originales participaron en el nacimiento de la Sociedad Mexicana de Ciencias Fisiológicas. Fue el origen de un importante centro de investigación a nivel nacional (CINVESTAV) y ha dado lugar a numerosos grupos y departamentos dentro del Instituto Nacional de Cardiología, como el Departamento de Válvulas en el basamento del edificio principal, el Departamento de Biología Molecular ubicado en el Anexo de Investigación y un laboratorio en la Unidad de Medicina Traslacional. El Departamento de Fisiología ha contribuido de manera importante al desarrollo de la investigación en el Instituto Nacional de Cardiología.

Four countries for science.

A personal retrospect is given on four decades in science in four countries - the UK, France, Germany and the USA. Some historical observations are made together with a time transect through scientific systems and institutions in the four countries.

The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML.

For two decades, leukaemia stem cells (LSCs) in chronic myeloid leukaemia (CML) and acute myeloid leukaemia (AML) have been advanced paradigms for the cancer stem cell field. In CML, the acquisition of the fusion tyrosine kinase BCR-ABL1 in a haematopoietic stem cell drives its transformation to become a LSC. In AML, LSCs can arise from multiple cell types through the activity of a number of oncogenic drivers and pre-leukaemic events, adding further layers of context and genetic and cellular heterogeneity to AML LSCs not observed in most cases of CML. Furthermore, LSCs from both AML and CML can be refractory to standard-of-care therapies and persist in patients, diversify clonally and serve as reservoirs to drive relapse, recurrence or progression to more aggressive forms. Despite these complexities, LSCs in both diseases share biological features, making them distinct from other CML or AML progenitor cells and from normal haematopoietic stem cells. These features may represent Achilles' heels against which novel therapies can be developed. Here, we review many of the similarities and differences that exist between LSCs in CML and AML and examine the therapeutic strategies that could be used to eradicate them.

Human genetics and genomics research in Ecuador: historical survey, current state, and future directions.

BACKGROUND: In South America, the history of human genetics is extensive and its beginnings go back to the onset of the twentieth century. In Ecuador, the historical record of human genetics and genomics research is limited. In this context, our work analyzes the current status and historical panorama of these fields, based on bibliographic searches in Scopus, Google Scholar, PubMed, and Web of Science. RESULTS: Our results determined that the oldest paper in human genetics coauthored by an Ecuadorian institution originates from the Central University of Ecuador in 1978. From a historical standpoint, the number of articles has increased since the 1990s. This growth has intensified and it is reflected in 137 manuscripts recorded from 2010 to 2019. Areas such as human population genetics, phylogeography, and forensic sciences are the core of genetics and genomics-associated research in Ecuador. Important advances have been made in the understanding of the bases of cancer, some genetic diseases, and congenital disorders. Fields such as pharmacogenetics and pharmacogenomics have begun to be explored during the last years. CONCLUSIONS: This work paints a comprehensive picture and provides additional insights into the future panorama of human genetic and genomic research in Ecuador as an example of an emerging, resource-limited country with interesting phylogeographic characteristics and public health implications.

What Does the History of Research on the Repair of DNA Double-Strand Breaks Tell Us?-A Comprehensive Review of Human Radiosensitivity.

Our understanding of the molecular and cellular response to ionizing radiation (IR) has progressed considerably. This is notably the case for the repair and signaling of DNA double-strand breaks (DSB) that, if unrepaired, can result in cell lethality, or if misrepaired, can cause cancer. However, through the different protocols, techniques, and cellular models used during the last four decades, the DSB repair kinetics and the relationship between cellular radiosensitivity and unrepaired DSB has varied drastically, moving from all-or-none phenomena to very complex mechanistic models. To date, personalized medicine has required a reliable evaluation of the IR-induced risks that have become a medical, scientific, and societal issue. However, the molecular bases of the individual response to IR are still unclear: there is a gap between the moderate radiosensitivity frequently observed in clinic but poorly investigated in the publications and the hyper-radiosensitivity of rare but well-characterized genetic diseases frequently cited in the mechanistic models. This paper makes a comprehensive review of semantic issues, correlations between cellular radiosensitivity and unrepaired DSB, shapes of DSB repair curves, and DSB repair biomarkers in order to propose a new vision of the individual response to IR that would be more coherent with clinical reality.

History and Current Status of Autophagy Research.

Autophagy is an evolutionarily conserved process in which eukaryotic bilayer membrane vesicles enclose intracellular contents and transport them to lysosomes for degradation. In the 1990s, Ohsumi et al. identified multiple autophagy-related genes in a yeast model. Functional homologues of almost all yeast autophagy-related genes were found in higher eukaryotes. In 2003, Klionsky et al. named these genes the Atg genes and studied the interactions between the proteins they encoded and their functions in autophagy. In April 2005, a new journal, Autophagy, was published that was edited by Klionsky. The number of autophagy research papers indexed by PubMed has increased each year. In 2016, Yoshinori Ohsumi won the Nobel Prize in Medicine or Physiology for his discovery of the autophagy mechanism. Autophagy has thus become a hot research area, which involves biology, medicine, botany and microbiology. Many researchers are actively exploring the relationship between non-selective and selective autophagy and various pathophysiological states in humans, and are studying the molecular mechanisms underlying autophagy regulation in various biological conditions, including cancer, neurodegenerative diseases, cardiovascular diseases, immune responses, development and ageing. This chapter focuses on the history and current status of autophagy research and highlights the milestones that contributed to the development of the field.